A combination, for use in treating cancer in an individual in need thereof, of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, wherein the first antibody is directed to an antigen presented on a tumor cell or in a tumor cell environment, and wherein the effector moiety is a mutant IL-2 effector moiety comprising at least one amino acid mutation that reduces or abolishes the affinity of the mutant IL-2 effector moiety to the α-subunit of the IL-2 receptor but preserves the affinity of the mutant IL-2 effector moiety to the intermediate-affinity IL-2 receptor, compared to the non-mutated IL-2 effector moiety; and (b) a second antibody selected from the group of (i) an IgG class antibody directed to Epidermal Growth Factor Receptor (EGFR), comprising the heavy chain variable domain of SEQ ID NO: 102 and the light chain variable domain of SEQ ID NO: 103, wherein the antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-engineered antibody, and (ii) an IgG class antibody directed to HER3, comprising the heavy chain variable domain of SEQ ID NO: 142 and the light chain variable domain of SEQ ID NO: 146, wherein the antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-engineered antibody. (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, wherein the first antibody is directed to an antigen presented on a tumor cell or in a tumor cell environment, and wherein the effector moiety is a mutant IL-2 effector moiety comprising at least one amino acid mutation that reduces or abolishes the affinity of the mutant IL-2 effector moiety to the α-subunit of the IL-2 receptor but preserves the affinity of the mutant IL-2 effector moiety to the intermediate-affinity IL-2 receptor, compared to the non-mutated IL-2 effector moiety; and (b) a second antibody selected from the group of (i) an IgG class antibody directed to Epidermal Growth Factor Receptor (EGFR), comprising the heavy chain variable domain of SEQ ID NO: 102 and the light chain variable domain of SEQ ID NO: 103, wherein the antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-engineered antibody, and (ii) an IgG class antibody directed to HER3, comprising the heavy chain variable domain of SEQ ID NO: 142 and the light chain variable domain of SEQ ID NO: 146, wherein the antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-engineered antibody. (i) an IgG class antibody directed to Epidermal Growth Factor Receptor (EGFR), comprising the heavy chain variable domain of SEQ ID NO: 102 and the light chain variable domain of SEQ ID NO: 103, wherein the antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-engineered antibody, and (ii) an IgG class antibody directed to HER3, comprising the heavy chain variable domain of SEQ ID NO: 142 and the light chain variable domain of SEQ ID NO: 146, wherein the antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-engineered antibody.